Navigation Links
ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
Date:9/9/2009

$1,781,000 $4,186,000 Other current liabilities 3,057,000 2,589,000 --------- --------- Total current liabilities 4,838,000 6,775,000 Long-term liabilities 363,000 982,000 Stockholders' equity 22,454,000 30,525,000 ---------- ---------- $27,655,000 $38,282,000 =========== ===========


                               THERMOGENESIS CORP.
                 Condensed Consolidated Statements of Operations
                                   (Unaudited)

                                Three Months Ended          Years Ended
                                     June 30,                  June 30,
                                2009         2008         2009         2008
                                ----         ----         ----         ----
    Net revenues            $4,023,000   $7,182,000  $19,799,000  $21,946,000

    Cost of revenues         3,617,000    4,832,000   14,106,000   14,976,000
                             ---------    ---------   ----------   ----------

      Gross profit             406,000    2,350,000    5,693,000    6,970,000
                               -------    ---------    ---------    ---------

    Expenses:
      Selling, general and   2,212,000    2,838,000    9,249,000   10,165,000
       administrative

      Research and
       development           1,306,000    2,157,000    5,222,000    7,172,000
                             ---------    ---------    ---------    ---------

        Total operating
         expenses            3,518,000    4,995,000   14,471,000   17,337,000

    Interest and other
     income, net    
'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
(Date:1/14/2014)... Washington, USA, and Cardiff, UK (PRWEB) January 13, 2014 ... photonics technology development leader with more than 20 years ... society for optics and photonics . Hainsey will serve ... are delighted to have Dr. Hainsey join SPIE as ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... Oct. 21 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... nationwide and internationally, is pleased to announce that Chairman, CEO ... Operations, will appear for one hour live on "Go Rogue ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... financial results on Wednesday, October 27, 2010, after the market ... call at 5:00 p.m. ET, which will be open to ... the company will review the financial results and discuss other ...
... and NEW YORK, Oct. 20 ACCESS ... ACCP ), a biopharmaceutical company leveraging its proprietary drug-delivery ... supportive care and diabetes, announced it has submitted additional ... formulations of many global top-100 injectable drugs, as a ...
Cached Biology Technology:Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network 2Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 2Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology 3
(Date:7/9/2014)... of Adlie penguins shows that the population is ... than previously estimated. Adlie penguins have long been ... understand the effects of climate change and fishing ... satellite imagery, researchers from Stony Brook University and ... that permits regular monitoring of Adlie penguins across ...
(Date:7/9/2014)... an economy driven by methane, the primary component of natural ... production boom. It has poised the country as a top ... over just how climate-friendly it is, according to an article ... news magazine of the American Chemical Society. , In the ... when burned as a fuel to produce electricity, methane emits ...
(Date:7/9/2014)... at the NIH,s National Center for Advancing ... treat sickle cell disease has been acquired ... candidate, Aes-103, is the first specifically developed ... sickle cell disease. Baxter now will advance ... approval and commercialization. , Sickle cell disease ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... 5, 2008 Scientists report online this week in ... of specialized gut immune cells to a gene associated ... inflammatory bowel disorder. The link to immune cells ... St. Louis because they and others believe Crohn,s disease ...
... found the key to engineering plants capable of thriving ... report published online on October 2nd in Current ... that is generally plentiful in the earth,s crustcauses particular ... where acidic environments turn the metal into a form ...
... the power of 21st century computing to confirm an idea ... cycles evolve faster. Their findings appear in the October 3rd ... consequence for the understanding of evolution made possible by the ... said senior author Michael Donoghue , the G. Evelyn ...
Cached Biology News:Form of Crohn's disease traced to disabled gut cells 2How to build crops that can beat aluminum's toxic effects 2Reproducing early and often is the key to rapid evolution in plants 2
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Biology Products: